



Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521

Email: influxhealthtech@gmail.com / info@influxhealthtech.com

Website: www.influxhealthtech.co.in

CIN: L24299MH2020PLC346825

July 10, 2026

To,
Listing Department,
National Stock Exchange Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400 051

Scrip Code – INFLUX

Dear Sir/Mam,

Sub.: Business Update for the Quarter Ended June 30, 2026 (Q1FY27)

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Business Update – Q1FY27

Influx Healthtech Limited: Capacity Expansion, Innovation & Market Leadership Driving Stakeholder Value Creation

FY27 Topline Growth Guided at 25–30% | EBITDA Margins Guided at ~20–22%

India, July 10, 2026: Influx Healthtech Limited, a leading innovation-driven CDMO, today provided a business update for the quarter ended June 30, 2026 (Q1FY27).

Key Highlights - Q1FY27

- Strong growth in the nutraceutical segment, with all other business verticals also reporting healthy growth.
- Favourable business mix and improved operating efficiencies, leading to stronger profitability and margin expansion.
- Enhanced working capital efficiency through better receivables and inventory management.
- Strong client retention, reflecting long-term customer relationships and consistent product quality.
- Strategically reallocated ₹10 Crs to expand the nutraceutical CDMO facility from approx. 35,000 sq. ft. to 75,000 sq. ft., expected to become operational by August 2026.
- Installed manufacturing capacity expected to increase by approximately 2.5x upon fully commissioning of the new facility



Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521

Email: influxhealthtech@gmail.com / info@influxhealthtech.com

Website: www.influxhealthtech.co.in

CIN: L24299MH2020PLC346825

Segmental Highlights - Q1FY27

- Nutraceuticals: Commissioned a new tablet granulation line with a processing capacity of ~480 kg/day, supporting production of approximately 24,000 bottles per day.
- Protein & Snack Bars: Witnessed strong demand across the protein and snack bar segment.
- Beverage Manufacturing: Building high-capacity beverage infrastructure, including canning, carbonated beverage and Tetra Pak lines with 10,000 bottles/hour capacity.
- Pet Nutrition: Expanding pet nutrition capacity from 16–18 tonnes/month towards 25 tonnes/month to address growing near-term customer demand. Additionally, ordered a high-capacity pet food extrusion line, increasing processing capability from 100–150 kg/hour to 1,000 kg/hour to support long-term growth.

Other Key Highlights

- Enhanced pet healthcare offerings through development of innovative, palatable pet chew formulations.
- Invested in innovative cosmetics machinery from China to create differentiated cream formulations with enhanced visual appeal.
- Expanded diversified product portfolio across more than 3,400 SKUs, enabling customised manufacturing solutions across healthcare and wellness categories.
- Progress in customer product registrations following successful Tanzania regulatory approval, supporting continued export expansion across Tanzania, Nigeria, Kenya and other international markets.

Outlook - FY27 and Beyond

The management remains confident in sustaining execution momentum into FY27, driven by:

- Commissioning and ramp-up of the new approx. 75,000 sq. ft. facility, targeted commissioning gradually from August 2026, together with higher utilisation at existing facilities, expected to deliver a 2.5x capacity uplift, once completely operational.
- Guidance: Topline growth expected to be approx. 25–30% in FY27, with EBITDA margins guided at ~20–22%.
- FY27 Strategy: Continued focus on scaling existing customer relationships and expanding into premium product categories, while strengthening the company's presence through Olahey Wellness Pvt. Ltd. and expanding product offerings across Clinical & Functional Nutrition, Cosmetic Innovation and Pet Nutrition categories.

About Influx Healthtech Limited

Influx Healthtech Limited is an innovation-driven CDMO with a diversified portfolio spanning nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care. The company differentiates itself through proprietary delivery formats, including its Quick Snap technology, and premium packaging innovations, supported by an expanding manufacturing infrastructure and a growing international regulatory footprint.



Regd. Office: 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai : 400067.

Factory: Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar - 401 404, Maharashtra.

Contact No.: +91 9820201063 / 8080333319 / 8411879521

Email: influxhealthtech@gmail.com / info@influxhealthtech.com

Website: www.influxhealthtech.co.in

CIN: L24299MH2020PLC346825

The above information is subject to limited review / audit by the Statutory Auditors of the Company. The company will continue to keep the stock exchanges informed of all material developments in compliance with applicable regulations.

We request you to take the above information on record.

Thanking you,
For Influx Healthtech Limited,

Munir Abdul Ganee Chandniwala
Managing Director
DIN: 08459582

For further information, please contact



Company
Influx Healthtech Limited

info@influxhealthtech.com



Investor relations consultants
Capital Bridge Advisory Service Private Limited

Raj Shah, CFA
Raj@capbridge.in
91 - 99259 11296

Hrishit Jhaveri, CFA
Hrishit@capbridge.in
91 - 90999 94345